drugset / Trial / NCT04950868

The Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression

NCT04950868

Phase 1 Active not recruiting 22 enrolled Verinder Sharma
NaSingle-groupOpen-labelTreatment

Summary

Postpartum depression is a serious disorder that affects approximately 14% of women who have recently given birth. Postpartum depression is either an episode of major depressive disorder (only low periods) or bipolar disorder (periods of lows and highs). Untreated postpartum depression can negatively affect the mother, the infant and the family. Antidepressants are the most used treatments; however, for many women these drugs are not useful, resulting in a pressing need for effective treatments for postpartum depression. Lack of sleep is common after delivery and can trigger depression in some women. Quetiapine, a drug used for bipolar disorder, major depressive disorder and occasionally sleeplessness has not been well studied in postpartum depression. This study aims to find out how mothers tolerate the drug and whether it is effective for postpartum depression. Results of this study may help investigators carry out a larger study comparing quetiapine and placebo (a sugar pill) in postpartum depression.

Timeline

Start
2022-03-18
Primary completion
2025-06-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 150 mg

Indications